Graticule Asia Macro Advisors LLC Clovis Oncology, Inc. Transaction History

Graticule Asia Macro Advisors LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $1.6 Million - $2.34 Million	-27,700 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $1.86 Million - $2.35 Million	27,700	27,700 $2.28 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Graticule Asia Macro Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Graticule Asia Macro Advisors LLC with notifications on news.